Osiris, Novartis Pharmaceuticals Corp. deal

The companies will develop therapeutics for tissue regeneration based on human mesenchymal stem cells (MSC). Novartis receives an exclusive

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE